Evidence map›Paper›PMID 34664885›Full record

ArticleMedicine2021

Time from first tumor manifestation to diagnosis in patients with GEP-NET: Results from a large German tertiary referral center.

Christine Koch, Esra Koca, Natalie Filmann, Gabriele Husmann, Jörg Bojunga

Open access · goldAbstract read
In one paragraph

Article in Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 6 countries.

Christine KochGoethe University Frankfurt, University Hospital, Department of Gastroenterology, Hepatology and Endocrinology, Frankfurt, Germany.ORCID 0000-0003-0901-9050
Esra KocaGoethe University Frankfurt, University Hospital, Department of Gastroenterology, Hepatology and Endocrinology, Frankfurt, Germany.
Natalie FilmannGoethe University Frankfurt, Department of Biostatistics and Mathematical Modeling, Frankfurt, Germany.
Gabriele HusmannGoethe University Frankfurt, University Hospital, University Cancer Center, Tumor Documentation, Frankfurt, Germany.
Jörg BojungaGoethe University Frankfurt, University Hospital, Department of Gastroenterology, Hepatology and Endocrinology, Frankfurt, Germany.
Goethe University Frankfurt · DE

Funding

Ipsen Biopharmaceuticals no
6 · The paper itself

Abstract

abstractPatients with neuroendocrine tumors (NET) often go through a long phase between onset of symptoms and initial diagnosis.Assessment of time to diagnosis and pre-clinical pathway in patients with gastroenteropancreatic NET (GEP-NET) with regard to metastases and symptoms.Retrospective analysis of patients with GEP-NET at a tertiary referral center from 1984 to 2019; inclusion criteria: Patients ≥18 years, diagnosis of GEP-NET; statistical analysis using non-parametrical methods.Four hundred eighty-six patients with 488 tumors were identified; median age at first diagnosis (478/486, 8 unknown) was 59 years; 52.9% male patients. Pancreatic NET: 143/488 tumors; 29.3%; small intestinal NET: 145/488 tumors, 29.7%. 128/303 patients (42.2%) showed NET specific and 122/486 (25%) patients other tumor-specific symptoms. 222/279 patients had distant metastases at initial diagnosis (187/222 liver metastases). 154/488 (31.6%) of GEP-NET were incidental findings. Median time from tumor manifestation (e.g., symptoms related to NET) to initial diagnosis across all entities was 19.5 (95% CI: 12-28) days. No significant difference in patients with or without distant metastases (median 73 vs 105 days, P = .42).A large proportion of GEP-NET are incidental findings and only about half of all patients are symptomatic at the time of diagnosis. We did not find a significant influence of the presence of metastases on time to diagnosis, which shows a large variability with a median of <30 days.

Indexed as

Time FactorsAdolescentAdultAgedAged, 80 and overFemaleGermanyHumansIntestinal NeoplasmsMaleMiddle AgedNeuroendocrine TumorsPancreatic NeoplasmsRetrospective StudiesStomach NeoplasmsTertiary Care Centers

Identifiers

PMID34664885
PMCPMC8448036
OpenAlexW3199861296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.